Advice
following a full submission
darunavir/cobicistat (Rezolsta®) is accepted for use within NHS Scotland.
Indication under review: In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. Genotypic testing should guide its use.
Pharmacokinetic studies have demonstrated that darunavir/cobicistat is bioequivalent (in terms of darunavir exposure) to ritonavir-boosted darunavir. No comparative efficacy studies have been reported.
Download detailed advice173KB (PDF)
Medicine details
- Medicine name:
- darunavir cobicistat (Rezolsta)
- SMC ID:
- 1081/15
- Indication:
- In combination with other antiretroviral medicinal products for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults aged 18 years or older. Genotypic testing should guide its use.
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Infections
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 10 August 2015